Zobrazeno 1 - 10
of 2 238
pro vyhledávání: '"Douglas A Johnson"'
Autor:
Hongxu Dong, Lindsay V Clark, Xiaoli Jin, Kossonou Anzoua, Larisa Bagmet, Pavel Chebukin, Elena Dzyubenko, Nicolay Dzyubenko, Bimal Kumar Ghimire, Kweon Heo, Douglas A Johnson, Hironori Nagano, Andrey Sabitov, Junhua Peng, Toshihiko Yamada, Ji Hye Yoo, Chang Yeon Yu, Hua Zhao, Stephen P Long, Erik J Sacks
Publikováno v:
PLoS ONE, Vol 16, Iss 1, p e0240390 (2021)
Miscanthus is a close relative of Saccharum and a potentially valuable genetic resource for improving sugarcane. Differences in flowering time within and between Miscanthus and Saccharum hinders intra- and interspecific hybridizations. A series of gr
Externí odkaz:
https://doaj.org/article/0c60e29a518e46f4bbf1ca9a761afd3e
Autor:
Xue Bai, MD, Aleigha R. Lawless, BS, Juliane A. Czapla, MS, Stefanie C. Gerstberger, MD, PhD, Benjamin C. Park, MD, Seungyeon Jung, BA, Rebecca Johnson, MN, Naoya Yamazaki, MD, PhD, Dai Ogata, MD, PhD, Yoshiyasu Umeda, MD, Caili Li, MB, Jun Guo, MD, PhD, Keith T. Flaherty, MD, Yasuhiro Nakamura, MD, PhD, Kenjiro Namikawa, MD, PhD, Georgina V. Long, MBBS, PhD, Alexander M. Menzies, MBBS, PhD, Douglas B. Johnson, MD, Ryan J. Sullivan, MD, Genevieve M. Boland, MD, PhD, Lu Si, MD
Publikováno v:
JAAD International, Vol 15, Iss , Pp 105-114 (2024)
Background: Anti-Program-Death-1 (PD-1) is a standard adjuvant therapy for patients with resected melanoma. We hypothesized that there are discrepancies in survival, recurrence pattern and toxicity to adjuvant PD-1 between different ethnicities and m
Externí odkaz:
https://doaj.org/article/e27b5891bd9c4bf4a452fb755d884e7b
Autor:
Ralina Karagenova, MS, Bao Xin Liang, BS, David J. Elpern, MD, Dylan E. Lee, MD, Casey M. Phan, MD, Douglas W. Johnson, MD
Publikováno v:
JAAD Case Reports, Vol 48, Iss , Pp 80-82 (2024)
Externí odkaz:
https://doaj.org/article/c64411aa411144a18ff7fb43a326a53a
Autor:
Pooja Middha, Rohit Thummalapalli, Michael J. Betti, Lydia Yao, Zoe Quandt, Karmugi Balaratnam, Cosmin A. Bejan, Eduardo Cardenas, Christina J. Falcon, David M. Faleck, Princess Margaret Lung Group, Matthew A. Gubens, Scott Huntsman, Douglas B. Johnson, Linda Kachuri, Khaleeq Khan, Min Li, Christine M. Lovly, Megan H. Murray, Devalben Patel, Kristin Werking, Yaomin Xu, Luna Jia Zhan, Justin M. Balko, Geoffrey Liu, Melinda C. Aldrich, Adam J. Schoenfeld, Elad Ziv
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-10 (2024)
Abstract Immune checkpoint inhibitor-mediated colitis (IMC) is a common adverse event of treatment with immune checkpoint inhibitors (ICI). We hypothesize that genetic susceptibility to Crohn’s disease (CD) and ulcerative colitis (UC) predisposes t
Externí odkaz:
https://doaj.org/article/46e01ed1d0cc4b39bd52631c3a872a9b
Autor:
Douglas B Johnson, Kylie Fletcher
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, improving outcomes for many patients. However, toxicities termed immune-related adverse events (irAEs) are limitations of these revolutionary treatments. These irAEs may resolve w
Externí odkaz:
https://doaj.org/article/71902b4475a548f1b06b7a09efc88722
Autor:
Jessica C Hassel, Alexander N Shoushtari, Omid Hamid, Takami Sato, Paul Nathan, Marcus O Butler, Jason J Luke, Richard D Carvajal, Leonel Hernandez-Aya, Douglas B Johnson, Laura Collins, Enrique Espinosa, Joseph J Sacco, Serge Leyvraz, Alexandra Ikeguchi, Matthew Rioth, Chris Holland, Josep M Piulats
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 6 (2024)
Background Tebentafusp, a bispecific (gp100×CD3) ImmTAC, significantly improved overall survival (OS) outcomes for HLA-A*02:01+ adult patients with untreated metastatic uveal melanoma (mUM) and showed promising survival in previously treated mUM wit
Externí odkaz:
https://doaj.org/article/b89b2a51187f4158bed6c6e774c8ce00
Autor:
Ying Wang, Carolin Ertl, Christina Schmitt, Linda Hammann, Rafaela Kramer, Ulrich Grabmaier, Florian Schöberl, David Anz, Ignazio Piseddu, Giulia Pesch, Julio Vera, Waltraud Froehlich, Ludwig Weckbach, Dirk Tomsitz, Carmen Loquai, Lisa Zimmer, Johanna Mangana, Reinhard Dummer, Ralf Gutzmer, Kai-Christian Klespe, Henner Stege, Frank Meiss, Kai-Martin Thoms, Patrick Terheyden, Paul J. Bröckelmann, Douglas B. Johnson, Lars E. French, Lucie Heinzerling
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 11 (2024)
BackgroundImmune checkpoint inhibitor (ICI)-induced myocarditis is a rare immune-related adverse event (irAE) with a fatality rate of 40%–46%. However, irMyocarditis can be asymptomatic. Thus, improved monitoring, detection and therapy are needed.
Externí odkaz:
https://doaj.org/article/0d24ababd2e842d890215bef5ee1389e
Autor:
Jarushka Naidoo, Igor Puzanov, Paolo A Ascierto, Marc S Ernstoff, Douglas B Johnson, Fei Ye, Mitchell S von Itzstein, David E Gerber, Benjamin Switzer, Aliyah Pabani, Hannah Burnette, Run Fan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 5 (2024)
Background Artificial intelligence (AI) chatbots have become a major source of general and medical information, though their accuracy and completeness are still being assessed. Their utility to answer questions surrounding immune-related adverse even
Externí odkaz:
https://doaj.org/article/10149fdee8db4c7899ea1632bcd5d0b9
Autor:
Xue Bai, Ahmed Shaheen, Charlotte Grieco, Paolo D. d’Arienzo, Florentia Mina, Juliane A. Czapla, Aleigha R. Lawless, Eleonora Bongiovanni, Umberto Santaniello, Helena Zappi, Dominika Dulak, Andrew Williamson, Rebecca Lee, Avinash Gupta, Caili Li, Lu Si, Martina Ubaldi, Naoya Yamazaki, Dai Ogata, Rebecca Johnson, Benjamin C. Park, Seungyeon Jung, Gabriele Madonna, Juliane Hochherz, Yoshiyasu Umeda, Yasuhiro Nakamura, Christoffer Gebhardt, Lucia Festino, Mariaelena Capone, Paolo Antonio Ascierto, Douglas B. Johnson, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies, Kenjiro Namikawa, Mario Mandala, Jun Guo, Paul Lorigan, Yana G. Najjar, Andrew Haydon, Pietro Quaglino, Genevieve M. Boland, Ryan J. Sullivan, Andrew J.S. Furness, Ruth Plummer, Keith T. Flaherty
Publikováno v:
EClinicalMedicine, Vol 71, Iss , Pp 102564- (2024)
Externí odkaz:
https://doaj.org/article/377d8aad4882472db54c2cd4b6fbb9b1
Autor:
Laura C Cappelli, Bernice Kwong, Jarushka Naidoo, Jonathan Leventhal, Mario E Lacouture, Meghan J Mooradian, Douglas B Johnson, Justine Cohen, Aparna Hegde, Steven T Chen, Riley Fadden, Leyre Zubiri, Shawn Kwatra, Ryan J Sullivan, Kerry L Reynolds, Allison Betof Warner, Yevgeniy R Semenov, Nicole R LeBoeuf, Krista M Rubin, Anna K Dewan, Alina Markova, Allireza Alloo, Daniel Q Bach, Amina Bougrine, Leeann Burton, Mariana Castells, Lauren Guggina, Victor Huang, Benjamin Kaffenberger, Daniela Kroshinsky, Cecilia Larocca, Jon McDunn, Jennifer Choi, Vinod Nambudiri, Caroline A Nelson, Anisha B Patel, Julia Pimkina, Johnathan Rine, Maxwell Sauder, Sheila Shaigany, Afreen Shariff
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 4 (2024)
With an increasing number of patients eligible for immune checkpoint inhibitors, the incidence of immune-related adverse events (irAEs) is on the rise. Dermatologic immune-related adverse events (D-irAEs) are the most common and earliest to manifest,
Externí odkaz:
https://doaj.org/article/0f9ad47d419c4ad4b3131ec90c49be9f